-
Product Insights
Leishmaniasis (Kala-Azar) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) - Drugs In Development, 2023’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drugs In Development, 2023’, provides an overview of the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paromomycin in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paromomycin in Leishmaniasis (Kala-Azar) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paromomycin in Leishmaniasis (Kala-Azar) Drug Details: Paromomycin is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CR-1301 in Intestinal Infection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CR-1301 in Intestinal Infection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CR-1301 in Intestinal InfectionDrug Details:CR-1301 is under development for the treatment of chronic...
-
Product Insights
Net Present Value Model: Metronidazole
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Metronidazole Drug Details Metronidazole (ATI-1501) is...
-
Product Insights
Net Present Value Model: ATI-2307
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ATI-2307 Drug Details T-2307 is under...
-
Product Insights
Net Present Value Model: Avigan
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Avigan Drug Details Favipiravir (Avigan) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – paromomycin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry paromomycin Drug Details Paromomycin is under development for the treatment of cutaneous leishmaniasis. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – T-2307
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry T-2307 Drug Details T-2307 is under development for the treatment of fungal infections including...